TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in ...
When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. We live in an increasing data-rich world, where forward-thinking organizations are harnessing the ...
Perspective Therapeutics announced data presentations at ASCO 2025 for its cancer treatment programs [212Pb]VMT-α-NET and [212Pb]VMT01. Perspective Therapeutics, Inc. announced that it will present ...
SEATTLE, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced ...
Oral presentation to highlight updated Phase 1 monotherapy safety and efficacy data for TOS-358, a covalent PI3Ka inhibitor ...
Most white collar jobs involve creating presentations. And this can be a time-consuming, laborious process. Presentations include data points, and ensuring that these data points remain accurate and ...
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results